Advertisement

The U.S. Food and Drug Administration has approved Boston Scientific Corp.'s Renegade HI-FLO Fathom Pre-Loaded System, developed to treat uterine fibroids and liver cancer.

The Renegade is designed for interventional radiologists to deliver "diagnostic, embolic and therapeutic materials" to a patient's circulatory system, the Natick company said in a news release . The device, to be made in eight configurations, combines the company's Renegade HI-FLO Microcatheter, pre-loaded with its Fathom-16 Steerable Guidewire.

SOURCE

Advertisement
Advertisement